Liquid biopsy predicts response to CAR-T for multiple myeloma
Multiple myeloma is difficult to treat because of the heterogeneity of genomic aberrations and responses to treatment. Currently, bone marrow examinations are used for genomic evaluation at diagnosis, at evaluation of minimal residual disease and at relapse. This is an invasive procedure, but it also carries the risk of false negatives due to spatial heterogeneity. […]
